PMC:5332029 / 6519-7276 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/5332029","sourcedb":"PMC","sourceid":"5332029","source_url":"https://www.ncbi.nlm.nih.gov/pmc/5332029","text":"Therefore the present study aims to systematically review and synthesize the literature on this topic and provide an updated overview (i.e. up to December 2015). We are specifically focused at looking at the cost-benefit of recognised evaluated treatments, as the results can be used to gain insight into how much society is spending on BPD, and potentially how much can be saved if effective therapy is offered. The information can be helpful in setting priorities for health care efficiency research as high societal costs present a strong argument in favour of prioritizing BPD treatments in reimbursement decisions, in terms of health insurance benefits for affected individuals and funding grants to provide accessible and effective treatment services.","tracks":[]}